Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.30 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | FRK | P42685 | 1/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.30 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.30 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.30 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.30 |
| ▸ | GCGR | P47871 | 1/20 | 0.30 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6665929 | 0.83 | TRPA1 (0.32) | TRPA1 | |
| SCHEMBL6666547 | 0.81 | TRPA1 (0.31) | TRPA1GCGR | |
| SCHEMBL3855008 | 0.71 | NSD3 (0.46) | LMNAPTGS2PRKD3MAP4K4FRK | |
| SCHEMBL12907335 | 0.70 | CYP11B1 (0.37) | LMNAPTGS2ALDH1A1 | |
| SCHEMBL7377819 | 0.67 | CYP11B1 (0.37) | LMNAPTGS2 | |
| SCHEMBL25147201 | 0.65 | NSD3 (0.46) | LMNAPTGS2ALDH1A1 | |
| SCHEMBL7404048 | 0.65 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL7310245 | 0.65 | CYP11B1 (0.34) | KDM4EALDH1A1 | |
| SCHEMBL3855448 | 0.64 | NSD3 (0.38) | LMNAPTGS2KDM4EALDH1A1 | |
| SCHEMBL6885776 | 0.64 | CYP2C19 (0.33) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127718-A1 | Substituted imidazoles | NOVO NORDISK A/S (DK) | 2004-07-01 | — | — | US | disclosed |
| US-20030181479-A1 | Substituted imidazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181479-A1 | Substituted imidazoles | HRH3, HRH4, HRH2 | LMNA 4725/4885PTGS2 922/4885KDM5A 1386/4885 |
| US-20040127718-A1 | Substituted imidazoles | HRH3, HRH4, HRH2 | LMNA 4725/4885PTGS2 922/4885KDM5A 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.